Grey Matters Announces September Opening of its First Brain Dedicated PET Neuroimaging Clinic in the U.S.

About this update from Grey Matters Health Inc

VANCOUVER, British Columbia, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the "Company" or "Grey Matters") (CSE: GREY) (FRANKFURT: AGW0) (OTC: AGNPF), a Canadian healthcare company, is pleased to announce that it plans to open its flagship NovaScan Neuroimaging ClinicsTM location next month in Davie, Florida and conduct a brain PET scan of its first patient by September 30th, 2026. "We are very pleased to announce the timeline of our planned opening", said Christopher J. Moreau CEO of Grey Matters Health. "Our team is working diligently to prepare for the launch of our flagship clinic featuring new U.S. FDA-cleared brain imaging technology and an elevated, patient focused approach to clinical services and care." The inaugural NovaScan Neuroimaging ClinicsTM location is at the HCA Florida University Medical Office Building in Davie, located on the campus of the HCA Florida University Hospital, and will be the first of its kind in the U.S. to provide brain dedicated PET scans to aid in the detection of Alzheimer's Disease (AD) and other forms of neurodegenerative diseases including frontotemporal dementia, Parkinson's, and Lewy Body Dementia, and will be additionally used for other select neuro-oncology applications. HCA Florida University Medical Office Building / Davie, Florida Brain PET scans for beta-amyloid plaque detection (associated with advancing AD) are covered by Medicare, Medicaid and private insurance for those 65+, with patients being referred to NovaScan Neuroimaging ClinicsTM by Neurologists, Geriatricians, and Primary Care Physicians. The clinic will feature the U.S. FDA-cleared CareMiBrain™ system, a ground-breaking, new seated diagnostic brain PET scanner, that does not need an integrated Computed Tomography (CT) component to produce high quality images, resulting in 25% less radiation exposure for patients. The CareMiBrainTM PET Brain Scanning System There are two recently U.S. FDA approved monoclonal antibody treatments for AD, which are also covered by Medicare, Medicaid and private insurance, designed to slow the progression of the disease – Leqembi (Eisai and Biogen) and Kisunla (Eli Lilly) - and both require a positive beta-amyloid brain scan (or spinal tap) in order for patients to be authorized to receive them. These drugs can dissolve amyloid plaque build-up in the brain and slow ...

View stock analysis, news, and events for Grey Matters Health Inc